Tests sacubitril/valsartan for heart dysfunction caused by cancer treatment
Tests sacubitril/valsartan in adult cancer survivors with early heart failure.
Plain-language title generated from the registry record
Registry title: Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Key facts
- Where
- Richmond, United StatesSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Source: NCT05194111, who can take part
Where in United States
- Virginia Commonwealth UniversityRichmond, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Virginia Commonwealth University
- Trial code
- NCT05194111
- Record updated
- 8 July 2026
- Original description
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.Read full original descriptionShow less
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
Inclusion: Age </= 39 years old at time of cancer diagnosis; Clinical records adequate to determine diagnosis and treatment regimen; Previous anthracycline chemotherapy; Global longitudinal strain <18% and/or; Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal but >/=40% on echocardiogram or cardiac magnetic resonance imaging (MRI); No symptoms of heart failure (shortness of breath, fatigue, swelling). Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Exclusion: Participation in another concurrent intervention study within 30 days or treatment with an investigational drug within 5 half-lives prior to randomization; Concomitant use of other angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), aliskiren, non-steroidal anti-inflammatories (NSAIDs) or lithium or the inability to stop these medications for the study; Active acute or chronic psychiatric illness that in the opinion of the investigator may prevent compliance with study instructions; Greater than mild mitral or aortic valve regurgitation/stenosis known pre-cancer therapy; Evidence of Coronavirus (COVID-19) within the last 60 days or recent (21 days) exposure to close personal contact with COVID-19; Greater than moderate tricuspid or pulmonary valve regurgitation/stenosis known pre-cancer therapy; Hemodynamically significant congenital heart disease in the opinion of the investigator (not including patent foramen ovale (PFO)/small atrial septal defect (ASD) or small ventricular septal defect (VSD)); Constrictive cardiomyopathy diagnosed pre-cancer therapy; Family history of genetic cardiomyopathy; Symptomatic heart disease based on New York Heart Association (NYHA) classification; Allergy to valsartan or sacubitril; Inability to complete cardiac magnetic resonance (CMR) or 6-minute walk test; Inability to measure non-invasive blood pressure and heart rate in the ambulatory/home setting; History of severe hypersensitivity reactions to gadolinium-based contrast agents (will perform limited cardiac imaging without contrast); Severe kidney disease (glomerular filtration rate (GFR) <30 milliliters (mL)/minute (min)/1.73 meters squared (m2)); Chronic hyperkalemia (>5millimoles per liter (mmol/L)); -Age <18 years; Inability to obtain consent from patient or legally authorized representative; Limited English or Spanish proficiency that in the opinion of the investigator may prevent understanding the content of the informed consent form or safely completing the study procedures; Greater than moderate pericardial effusion; Evidence of infiltrative cardiomyopathy; Pregnant/lactating.